A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cardiology"
DOI: 10.1002/clc.22687
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) downregulates low‐density lipoprotein (LDL) receptors, thereby leading to a rise in circulating LDL cholesterol (LDL‐C). RG7652 is a fully human monoclonal antibody against PCSK9. This placebo‐controlled, phase 1 ascending‐dose… read more here.
Keywords: ldl cholesterol; proprotein convertase; ldl; subtilisin kexin ... See more keywords
The role of proprotein convertase subtilisin/kexin type-9 concentration and paraoxonase 1 activities in the blood of women with polycystic ovary syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Environmental toxicology and pharmacology"
DOI: 10.1016/j.etap.2021.103612
Abstract: This study aimed to evaluate the concentration of proprotein convertase subtilisin/kexin type-9 and the activities of paraoxonase 1 in women with and without polycystic ovary syndrome (PCOS). We found significant higher PCSK9, whereas lower high-density… read more here.
Keywords: paraoxonase activities; proprotein convertase; convertase subtilisin; subtilisin kexin ... See more keywords
The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2019.06.008
Abstract: BACKGROUND Trials have demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues have limited their use in community practice. OBJECTIVE The aim… read more here.
Keywords: community; community practice; statin; convertase subtilisin ... See more keywords
Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2019.12.003
Abstract: BACKGROUND Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) significantly lower the levels of low-density lipoprotein and very-low-density lipoproteins (VLDL), but their effect on postprandial lipoprotein metabolism in dyslipidemic subjects is unclear. OBJECTIVE This… read more here.
Keywords: triglyceride rich; proprotein convertase; cholesterol; postprandial responses ... See more keywords
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2021.02.005
Abstract: BACKGROUND Proprotein convertase subtilisin/kexin type-9 (PCSK9) is an enzyme promoting the degradation of low-density lipoprotein receptors (LDL-R) in hepatocytes. Inhibition of PCSK9 has emerged as a novel target for lipid-lowering therapy. Monocytes are crucially involved… read more here.
Keywords: proprotein convertase; disease; monocyte subsets; pcsk9 levels ... See more keywords
Lignans from the fruits of Schisandra chinensis (Turcz.) Baill inhibit proprotein convertase subtilisin/kexin type 9 expression.
Sign Up to like & getrecommendations! Published in 2017 at "Phytochemistry"
DOI: 10.1016/j.phytochem.2017.01.010
Abstract: Bioactivity-guided fractionation of the fruits of Schisandra chinensis, using the proprotein convertase subtilisin-kexin type 9 (PCSK9) mRNA expression screening assay, led to isolation of two previously unknown lignans, 14-tigloylschinlignan D and rel-(7R, 8R, 7'R, 8'R)-manglisin… read more here.
Keywords: proprotein convertase; subtilisin kexin; expression; convertase subtilisin ... See more keywords
Emerging role of proprotein convertase subtilisin/kexin type‐9 (PCSK‐9) in inflammation and diseases
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology and Applied Pharmacology"
DOI: 10.1016/j.taap.2019.03.018
Abstract: ABSTRACT Proprotein convertase subtilisin/kexin type‐9 (PCSK9) is most recognized serine protease for its role in cardiovascular diseases (CVD). PCSK9 regulates plasma low‐density lipoprotein cholesterol (LDL‐C) levels by selectively targeting hepatic LDL receptors (LDLR) for degradation,… read more here.
Keywords: proprotein convertase; subtilisin kexin; pcsk9; role ... See more keywords
PERSISTENCE AND ADHERENCE WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN CLINICAL PRACTICE
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33548-9
Abstract: Background: Elevated low-density lipoprotein cholesterol (LDL-C) is associated with premature atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have shown reductions in LDL-C levels in patients uncontrolled by statin and/or ezetimibe therapy. read more here.
Keywords: proprotein convertase; subtilisin kexin; kexin type; type inhibitors ... See more keywords
ASSOCIATIONS BETWEEN CIRCULATING LEVELS OF PLASMA OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 AND VASCULAR OUTCOMES IN AFRICAN AMERICAN DIABETIC PATIENTS
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)32365-9
Abstract: Studies showed conflicting results for the association of circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) with glycemic parameters and risk of type 2 diabetes. Whether plasma levels of PCSK9 could directly influence vascular function is… read more here.
Keywords: proprotein convertase; subtilisin kexin; kexin type; type ... See more keywords
LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)32320-4
Abstract: LIB003 is a 77 kDa recombinant fusion protein consisting of an adnectin, derived from the 10th type III domain of human fibronectin and targeted with high affinity to proprotein convertase subtilisin/kexin type 9 (PCSK9), and… read more here.
Keywords: fusion protein; subtilisin kexin; kexin type; convertase subtilisin ... See more keywords
ACUTE KIDNEY INJURY: A RARE CONSEQUENCE OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR USE
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)33011-4
Abstract: Acute kidney injury (AKI) is not a reported side effect of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK-9) inhibitor therapy. PCSK-9 inhibitors are cleared via the reticuloendothelial system and are considered nontoxic to the kidney. A… read more here.
Keywords: kidney injury; proprotein convertase; acute kidney; subtilisin kexin ... See more keywords